Alejandro Santos Leal, MD
Endocrinology, Diabetes & Metabolism · Manassas, VANPI 1780847111
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Lilly USA, LLC at 25.3% of the total.
Across 346 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$738
- Boehringer Ingelheim$352
- Mannkind Corporation$291
- Amgen$285
- Sanofi-aventis U.S. LLC$273
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,15394%
- Education$3345%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 98 | $1,659 |
| Novo Nordisk | 36 | $738 |
| Boehringer Ingelheim | 19 | $352 |
| Mannkind Corporation | 14 | $291 |
| Amgen | 16 | $285 |
| Sanofi-aventis U.S. LLC | 15 | $273 |
| BETA Bionics, Inc. | 9 | $252 |
| Xeris Pharmaceuticals, Inc. | 11 | $240 |
| Bayer | 12 | $226 |
| Insulet Corporation | 11 | $207 |
| Amneal Pharmaceuticals LLC | 10 | $182 |
| Antares Pharma, Inc. | 8 | $169 |
| IBSA Pharma Inc. | 8 | $164 |
| Merck | 9 | $152 |
| AbbVie | 7 | $151 |
| Corcept Therapeutics | 7 | $130 |
| Novartis | 6 | $129 |
| Recordati_rare_diseases_inc. | 6 | $116 |
| Tandem Diabetes Care, Inc. | 5 | $108 |
| AstraZeneca | 5 | $96 |
| Madrigal Pharmaceuticals | 4 | $84 |
| Pfizer | 4 | $78 |
| Tolmar, Inc. | 4 | $69 |
| Dexcom, Inc. | 2 | $60 |
| Sequel Med Tech, LLC | 2 | $48 |
| Amarin Pharma, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $32 |
| Radius Health, Inc. | 2 | $28 |
| Abbott | 2 | $28 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Medtronic | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Clarus Therapeutics Inc. | 2 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$6,546 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 186 | $440,655 |
| OzempicSemaglutide | 187 | $374,156 |
| TrulicityDulaglutide | 180 | $310,623 |
| MounjaroTirzepatide | 132 | $216,003 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 149 | $209,924 |
| JardianceEmpagliflozin | 123 | $155,677 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 105 | $145,581 |
| RybelsusSemaglutide | 54 | $115,820 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $89,342 |
| Xigduo XrDapaglifloz Propaned/Metformin | 70 | $75,953 |
| Cinacalcet Hcl | 42 | $61,168 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $58,718 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $56,690 |
| FarxigaDapagliflozin Propanediol | 45 | $56,679 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $52,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskXultophy 100-3.6, Ozempic, Rybelsus, Novolog | $738 | $935,006438 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,659 | $531,982334 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $352 | $384,928285 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $273 | $145,581105 claims |
| MerckJanuvia, Janumet Xr | $152 | $71,87552 claims |
| AstraZenecaFarxiga | $96 | $56,67945 claims |
| AmgenProlia | $285 | $20,96212 claims |
| AbbVieSynthroid | $151 | $4,15251 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $182 | $3,570299 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Manassas
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.